Entellus Medical, Inc. (NASDAQ:ENTL) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report released on Saturday.

A number of other equities research analysts have also issued reports on ENTL. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, April 25th. Canaccord Genuity lowered shares of Entellus Medical from a “buy” rating to a “hold” rating and cut their price target for the company from $22.00 to $18.00 in a report on Thursday, May 4th. William Blair restated an “outperform” rating on shares of Entellus Medical in a report on Wednesday, May 10th. ValuEngine lowered shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 23rd. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a report on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.83.

Shares of Entellus Medical (ENTL) traded up 0.12% during mid-day trading on Friday, reaching $17.30. 131,057 shares of the company were exchanged. The firm’s market capitalization is $438.92 million. Entellus Medical has a 12 month low of $11.47 and a 12 month high of $22.63. The company’s 50 day moving average price is $17.14 and its 200 day moving average price is $14.96.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The firm’s revenue was up 18.0% compared to the same quarter last year. Equities analysts anticipate that Entellus Medical will post ($1.62) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Entellus Medical, Inc. (ENTL) Lifted to Buy at BidaskClub” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/19/entellus-medical-inc-entl-lifted-to-buy-at-bidaskclub.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Frontier Capital Management Co. LLC increased its position in shares of Entellus Medical by 85.0% in the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock worth $14,347,000 after buying an additional 397,953 shares during the last quarter. First Light Asset Management LLC increased its position in shares of Entellus Medical by 25.7% in the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock worth $8,486,000 after buying an additional 104,919 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Entellus Medical by 14.2% in the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock worth $8,036,000 after buying an additional 60,471 shares during the last quarter. Archon Capital Management LLC increased its position in shares of Entellus Medical by 34.3% in the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock worth $7,929,000 after buying an additional 122,171 shares during the last quarter. Finally, Kingdon Capital Management L.L.C. increased its position in shares of Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after buying an additional 199,615 shares during the last quarter. 67.61% of the stock is currently owned by hedge funds and other institutional investors.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.